PureTech Health PLC (PRTC)vsVertex Pharmaceuticals Inc (VRTX)
PRTC
PureTech Health PLC
$15.74
-0.79%
HEALTHCARE · Cap: $383.51M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 187684% more annual revenue ($12.00B vs $6.39M). VRTX leads profitability with a 32.9% profit margin vs 7.9%. PRTC trades at a lower P/E of 9.3x. VRTX earns a higher WallStSmart Score of 66/100 (B-).
PRTC
Buy51
out of 100
Grade: C-
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.0%
Fair Value
$79.56
Current Price
$15.73
$63.83 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 61.5% YoY
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Trading at 10.0x book value
Smaller company, higher risk/reward
7.9% margin — thin
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : PRTC
The strongest argument for PRTC centers on P/E Ratio, EPS Growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : PRTC
The primary concerns for PRTC are Price/Book, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
PRTC profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
PRTC carries more volatility with a beta of 0.69 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 51/100), backed by strong 32.9% margins. PRTC offers better value entry with a 78.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
PureTech Health PLC
HEALTHCARE · BIOTECHNOLOGY · USA
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?